MétaCan
Menu
Back to cohort
Record W4396764086 · doi:10.1016/s0140-6736(24)00533-6

Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK

2024· article· en· W4396764086 on OpenAlexaboutno aff
Rebecca L. Gould, Christopher McDermott, Benjamin J. Thompson, Charlotte Rawlinson, Matthew Bursnall, Mike Bradburn, Pavithra Kumar, Emily Turton, David A. White, Marc Serfaty, Christopher D. Graham, Lance M. McCracken, Laura H. Goldstein, Ammar Al‐Chalabi, Richard W. Orrell, Timothy L. Williams, Rupert Noad, Idris Baker, Christina Faull, Thomas Lambert, Suresh Kumar Chhetri, John Ealing, Anthony Hanratty, Aleksandar Radunović, Nushan Gunawardana, G.A. MEADOWS, George Gorrie, Tracey Young, Vanessa Lawrence, Cindy Cooper, Pamela J. Shaw, Robert Howard, Penny Andreou, Dynameni Androulaki-Korakaki, Claire Blakeley, G. Bridges, Iain C. Campbell, Brittany Davenport, Annily Dee, Nicola Drewry, John E. Flood, Annemieke Fox, Melissa Girling, Ruth Glew, Nick Hartley, Sian Hocking, Mark Howell, Anju Keetharuth, Selina M Makin, Jessica Marsh, Emily Mayberry, Alexa McDonald, R.J. McPartland, Steven Meldrum, Amanda Mobley, Donnchadh Murphy, Marie O’Brien, Mark Oliver, Darshna Patel, Emma Phipps, Jessica Read, Rhys Roberts, Natasha Rooney, Carla Smith, Jo Statham, Cara Thompson, Priya Varma, Anne M. Walker, Simon Waterhouse

Bibliographic record

VenueThe Lancet · 2024
Typearticle
Languageen
FieldMedicine
TopicAmyotrophic Lateral Sclerosis Research
Canadian institutionsnot available
FundersNIHR Sheffield Biomedical Research CentreNIHR School for Primary Care ResearchMedical Research CouncilUniversity College London Hospitals NHS Foundation TrustHealth Technology Assessment ProgrammeEconomic and Social Research CouncilNIHR Maudsley Biomedical Research CentreUniversity College LondonKing's College LondonMotor Neurone Disease AssociationNational Institute for Health and Care ResearchEU Joint Programme – Neurodegenerative Disease Research
KeywordsQuality of life (healthcare)Acceptance and commitment therapyMindfulnessDiseaseMedicineRandomized controlled trialMotor neuronPhysical therapyPsychologyPhysical medicine and rehabilitationPsychiatryClinical psychologyNursingInternal medicineIntervention (counseling)

Abstract

fetched live from OpenAlex

BACKGROUND: Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease. METHODS: We conducted a parallel, multicentre, two-arm randomised controlled trial in 16 UK motor neuron disease care centres or clinics. Eligible participants were aged 18 years or older with a diagnosis of definite or laboratory-supported probable, clinically probable, or possible familial or sporadic amyotrophic lateral sclerosis; progressive muscular atrophy; or primary lateral sclerosis; which met the World Federation of Neurology's El Escorial diagnostic criteria. Participants were randomly assigned (1:1) to receive up to eight sessions of ACT adapted for people with motor neuron disease plus usual care or usual care alone by a web-based system, stratified by site. Participants were followed up at 6 months and 9 months post-randomisation. Outcome assessors and trial statisticians were masked to treatment allocation. The primary outcome was quality of life using the McGill Quality of Life Questionnaire-Revised (MQOL-R) at 6 months post-randomisation. Primary analyses were multi-level modelling and modified intention to treat among participants with available data. This trial was pre-registered with the ISRCTN Registry (ISRCTN12655391). FINDINGS: Between Sept 18, 2019, and Aug 31, 2022, 435 people with motor neuron disease were approached for the study, of whom 206 (47%) were assessed for eligibility, and 191 were recruited. 97 (51%) participants were randomly assigned to ACT plus usual care and 94 (49%) were assigned to usual care alone. 80 (42%) of 191 participants were female and 111 (58%) were male, and the mean age was 63·1 years (SD 11·0). 155 (81%) participants had primary outcome data at 6 months post-randomisation. After controlling for baseline scores, age, sex, and therapist clustering, ACT plus usual care was superior to usual care alone for quality of life at 6 months (adjusted mean difference on the MQOL-R of 0·66 [95% CI 0·22-1·10]; d=0·46 [0·16-0·77]; p=0·0031). Moderate effect sizes were clinically meaningful. 75 adverse events were reported, 38 of which were serious, but no adverse events were deemed to be associated with the intervention. INTERPRETATION: ACT plus usual care is clinically effective for maintaining or improving quality of life in people with motor neuron disease. As further evidence emerges confirming these findings, health-care providers should consider how access to ACT, adapted for the specific needs of people with motor neuron disease, could be provided within motor neuron disease clinical services. FUNDING: National Institute for Health and Care Research Health Technology Assessment and Motor Neurone Disease Association.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.007
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.063
GPT teacher head0.355
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations32
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueThe LancetSame topicAmyotrophic Lateral Sclerosis ResearchFrench-language works237,207